TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

DelveInsight's "TRYVIO/JERAYGO Market Size, Forecast, and Market Insight Report" highlights the details around TRYVIO/JERAYGO ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Mar. 27, 2025 — A research team has investigated structural changes in kidneys of patients with hypertension and type 2 diabetes. The results show that high blood pressure can lead to ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria ...

Mendelian randomization (MR) represents a valuable methodology to address the causal relationships between an exposure and an ...

New research reveals that lower proportions of specific sleep stages are associated with reduced brain volume in regions vulnerable to the development of Alzheimer's disease over time. Results show ...

Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a serious condition that can impair blood flow, ...

Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor. (B.Z., E.J.S., D.A.L.) Department of Neurology ...